Tirzepatide (CAS 2023788-19-2)/tirzepatide peptide

Tirzepatide (CAS 2023788-19-2) is a high-purity dual GIP/GLP – 1 receptor agonist metabolic API with a synergistic metabolic regulatory mechanism. It simultaneously activates GIP and GLP – 1 receptors, enhancing glucose – dependent insulin secretion, inhibiting glucagon release, reducing food intake and slowing gastric emptying. It shows remarkable efficacy in lowering blood glucose of type 2 diabetes patients and promoting weight loss in overweight/obese people, and also exerts positive effects on improving lipid metabolism and insulin sensitivity. Its lyophilized form ensures stable bioactivity and low impurity content, serving as a reliable active ingredient for metabolic disease pharmaceutical R&D.

Tailored for pharmaceutical manufacturers and metabolic disease research institutions, this product complies with strict international quality and regulatory standards. It meets the core demand for dual – target metabolic raw materials, supporting the development of formulations for type 2 diabetes and obesity treatment. Its stable peptide structure and lyophilized preparation allow for flexible formulation design such as subcutaneous injection preparations and clinical trial applications.